Subcutaneous Injection of Interleukin 12 Induces Systemic Inflammatory Responses in Humans: Implications for the Use of IL-12 As Vaccine Adjuvant

Overview

Journal Cancer Immunol Immunother

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 2005 Feb 5

PMID 15693137

Citations 7

Authors

Johanna E A Portielje

Wim H J Kruit

Anke J M Eerenberg

Martin Schuler

Alex Sparreboom

Cor H J Lamers

Jan-Willem Gratama

Gerrit Stoter

Christoph Huber

C Erik Hack

Affiliations

Soon will be listed here.

Abstract

Interleukin 12 (IL-12) is a cytokine with important regulatory functions bridging innate and adaptive immunity. It has been proposed as an immune adjuvant for vaccination therapy of infectious diseases and malignancies. The inflammatory properties of IL-12 play an important role in the adjuvant effect. We studied the effect of s.c. injections of recombinant human IL-12 (rHuIL-12) in 26 patients with renal cell cancer and demonstrated dose-dependent systemic activation of multiple inflammatory mediator systems in humans. rHuIL-12 at a dose of 0.5 microg/kg induced degranulation of neutrophils with a significant increase in the plasma levels of elastase (p < 0.05) and lactoferrin (p = 0.01) at 24 h. Additionally, rHuIL-12 injection mediated the release of lipid mediators, as demonstrated by a sharp increase in the plasma secretory phospholipase A2 (sPLA2) level (p = 0.003). rHuIL-12, when administered at a dose of 0.1 microg/kg, showed minimal systemic effects. In conclusion, when IL-12 is used as an adjuvant, doses should not exceed 0.1 microg/kg, in order to avoid severe systemic inflammatory responses.

Citing Articles

Synthesis, Characterization, and Cytokinome Profile of IL-12-Loaded PLGA Nanospheres.

Lacinski R, Markel J, Noore J, Pratt H, Lindsey B J Immunol Res. 2022; 2022:6993187.

PMID: 35465347 PMC: 9023212. DOI: 10.1155/2022/6993187.

IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice.

Thomas E, Meza-Perez S, Bevis K, Randall T, Gillespie G, Langford C J Ovarian Res. 2016; 9(1):70.

PMID: 27784340 PMC: 5082415. DOI: 10.1186/s13048-016-0282-3.

Do schistosome vaccine trials in mice have an intrinsic flaw that generates spurious protection data?.

Wilson R, Li X, Castro-Borges W Parasit Vectors. 2016; 9:89.

PMID: 26888413 PMC: 4756456. DOI: 10.1186/s13071-016-1369-9.

Localized immunotherapy via liposome-anchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity.

Kwong B, Gai S, Elkhader J, Wittrup K, Irvine D Cancer Res. 2013; 73(5):1547-58.

PMID: 23436794 PMC: 3594475. DOI: 10.1158/0008-5472.CAN-12-3343.

Enhancement of specific cellular immune response induced by glycosyl-phosphatidylinositol-anchored BCR/ABL and mIL-12.

Tao K, Li Y, Wang D, Qi J, Deng Y, Wang H Cancer Biol Ther. 2011; 12(10):881-7.

PMID: 22024730 PMC: 3280903. DOI: 10.4161/cbt.12.10.17674.

References

Pruzanski W, Vadas P . Phospholipase A2--a mediator between proximal and distal effectors of inflammation. Immunol Today. 1991; 12(5):143-6. DOI: 10.1016/S0167-5699(05)80042-8. View

Pfeilschifter J, Schalkwijk C, Briner V, van den Bosch H . Cytokine-stimulated secretion of group II phospholipase A2 by rat mesangial cells. Its contribution to arachidonic acid release and prostaglandin synthesis by cultured rat glomerular cells. J Clin Invest. 1993; 92(5):2516-23. PMC: 288437. DOI: 10.1172/JCI116860. View

Ogilvie A, Hack C, Wagstaff J, van Mierlo G, Erenberg A, Thomsen L . IL-1 beta does not cause neutrophil degranulation but does lead to IL-6, IL-8, and nitrite/nitrate release when used in patients with cancer. J Immunol. 1996; 156(1):389-94. View

Smith G, Ward R, McGuigan L, Rajkovic I, Scott K . Measurement of human phospholipase A2 in arthritis plasma using a newly developed sandwich ELISA. Br J Rheumatol. 1992; 31(3):175-8. DOI: 10.1093/rheumatology/31.3.175. View

Hurteau J, Blessing J, DeCesare S, Creasman W . Evaluation of recombinant human interleukin-12 in patients with recurrent or refractory ovarian cancer: a gynecologic oncology group study. Gynecol Oncol. 2001; 82(1):7-10. DOI: 10.1006/gyno.2001.6255. View

Bussolati B, Mariano F, Cignetti A, Guarini A, Cambi V, Foa R . Platelet-activating factor synthesized by IL-12-stimulated polymorphonuclear neutrophils and NK cells mediates chemotaxis. J Immunol. 1998; 161(3):1493-500. View

Keller E, Wanagat J, Ershler W . Molecular and cellular biology of interleukin-6 and its receptor. Front Biosci. 1996; 1:d340-57. DOI: 10.2741/a136. View

Portielje J, Kruit W, Eerenberg A, Schuler M, Sparreboom A, Lamers C . Interleukin 12 induces activation of fibrinolysis and coagulation in humans. Br J Haematol. 2001; 112(2):499-505. DOI: 10.1046/j.1365-2141.2001.02592.x. View

Portielje J, Kruit W, Schuler M, Beck J, Lamers C, Stoter G . Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer. Clin Cancer Res. 2000; 5(12):3983-9. View

10.

Downey G . Mechanisms of leukocyte motility and chemotaxis. Curr Opin Immunol. 1994; 6(1):113-24. DOI: 10.1016/0952-7915(94)90042-6. View

11.

Schroder J, Mrowietz U, Morita E, Christophers E . Purification and partial biochemical characterization of a human monocyte-derived, neutrophil-activating peptide that lacks interleukin 1 activity. J Immunol. 1987; 139(10):3474-83. View

12.

Fallarino F, Uyttenhove C, Boon T, Gajewski T . Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide-pulsed peripheral blood mononuclear cells by coadministration of recombinant murine interleukin-12. Int J Cancer. 1999; 80(2):324-33. DOI: 10.1002/(sici)1097-0215(19990118)80:2<324::aid-ijc25>3.0.co;2-d. View

13.

Van Dullemen H, Wolbink G, Wever P, van der Poll T, Hack C, Tytgat G . Reduction of circulating secretory phospholipase A2 levels by anti-tumor necrosis factor chimeric monoclonal antibody in patients with severe Crohn's disease. Relation between tumor necrosis factor and secretory phospholipase A2 in healthy humans.... Scand J Gastroenterol. 1998; 33(10):1094-8. DOI: 10.1080/003655298750026813. View

14.

Motzer R, Rakhit A, Schwartz L, Olencki T, Malone T, Sandstrom K . Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin Cancer Res. 1998; 4(5):1183-91. View

15.

Carlos T, Clark R, Schiding J, Kochanek P . Expression of endothelial adhesion molecules and recruitment of neutrophils after traumatic brain injury in rats. J Leukoc Biol. 1997; 61(3):279-85. DOI: 10.1002/jlb.61.3.279. View

16.

Curtsinger J, Schmidt C, Mondino A, Lins D, Kedl R, Jenkins M . Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells. J Immunol. 1999; 162(6):3256-62. View

17.

Pruijt J, Fibbe W, Laterveer L, Pieters R, Lindley I, Paemen L . Prevention of interleukin-8-induced mobilization of hematopoietic progenitor cells in rhesus monkeys by inhibitory antibodies against the metalloproteinase gelatinase B (MMP-9). Proc Natl Acad Sci U S A. 1999; 96(19):10863-8. PMC: 17974. DOI: 10.1073/pnas.96.19.10863. View

18.

Colombo M, Modesti A, Parmiani G, Forni G . Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. Cancer Res. 1992; 52(18):4853-7. View

19.

Lauw F, Dekkers P, Te Velde A, Speelman P, Levi M, Kurimoto M . Interleukin-12 induces sustained activation of multiple host inflammatory mediator systems in chimpanzees. J Infect Dis. 1999; 179(3):646-52. DOI: 10.1086/314636. View

20.

van der Poll T, Levi M, van Deventer S, ten Cate H, Haagmans B, Biemond B . Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees. Blood. 1994; 83(2):446-51. View